Literature DB >> 29152046

Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8.

Peter Larson1, Tamara A Kucaba1, Zhengming Xiong1, Michael Olin1, Thomas S Griffith1, David M Ferguson1.   

Abstract

A series of N1-modified imidazoquinolines were synthesized and screened for Toll-like receptors (TLR) 7 and 8 activities to identify recognition elements that confer high affinity binding and selectivity. These receptors are key targets in the development of immunomodulatory agents that signal the NF-κB mediated transcription of pro-inflammatory chemokines and cytokines. Results are presented showing both TLR7/8 activations are highly correlated to N1-substitution, with TLR8 selectivity achieved through inclusion of an ethyl-, propyl-, or butylamino group at this position. While the structure-activity relationship analysis indicates TLR7 activity is less sensitive to N1-modification, extension of the aminoalkyl chain length to pentyl and p-methylbenzyl elicited high affinity TLR7 binding. Cytokine profiles are also reported that show the pure TLR8 agonist [4-amino-2-butyl-1-(2-aminoethyl)-7-methoxycarbonyl-1H-imidazo[4,5-c]quinoline] induces higher levels of IL-1β, IL-12, and IFNγ when compared with TLR7 selective or mixed TLR7/8 agonists. The results are consistent with previous work suggesting TLR8 agonists are Th1 polarizing and may help promote cell-mediated immunity.

Entities:  

Year:  2017        PMID: 29152046      PMCID: PMC5683703          DOI: 10.1021/acsmedchemlett.7b00256

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  14 in total

1.  Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848.

Authors:  Marion Jurk; Florian Heil; Jörg Vollmer; Christian Schetter; Arthur M Krieg; Hermann Wagner; Grayson Lipford; Stefan Bauer
Journal:  Nat Immunol       Date:  2002-06       Impact factor: 25.606

2.  Synthesis and Evaluation of Conjugates of Novel TLR7 Inert Ligands as Self-Adjuvanting Immunopotentiators.

Authors:  Dong Gao; Yu Liu; Yuwen Diao; Ningning Gao; Zhulin Wang; Wenqi Jiang; Guangyi Jin
Journal:  ACS Med Chem Lett       Date:  2015-01-30       Impact factor: 4.345

3.  Structural Analysis Reveals that Toll-like Receptor 7 Is a Dual Receptor for Guanosine and Single-Stranded RNA.

Authors:  Zhikuan Zhang; Umeharu Ohto; Takuma Shibata; Elena Krayukhina; Masato Taoka; Yoshio Yamauchi; Hiromi Tanji; Toshiaki Isobe; Susumu Uchiyama; Kensuke Miyake; Toshiyuki Shimizu
Journal:  Immunity       Date:  2016-10-11       Impact factor: 31.745

4.  Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

Authors:  Keith B Gorden; Kevin S Gorski; Sheila J Gibson; Ross M Kedl; William C Kieper; Xiaohong Qiu; Mark A Tomai; Sefik S Alkan; John P Vasilakos
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

5.  Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway.

Authors:  Hiroaki Hemmi; Tsuneyasu Kaisho; Osamu Takeuchi; Shintaro Sato; Hideki Sanjo; Katsuaki Hoshino; Takao Horiuchi; Hideyuki Tomizawa; Kiyoshi Takeda; Shizuo Akira
Journal:  Nat Immunol       Date:  2002-01-22       Impact factor: 25.606

6.  Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands.

Authors:  Hiromi Tanji; Umeharu Ohto; Takuma Shibata; Kensuke Miyake; Toshiyuki Shimizu
Journal:  Science       Date:  2013-03-22       Impact factor: 47.728

7.  Discovery of Imidazoquinolines with Toll-Like Receptor 7/8 Independent Cytokine Induction.

Authors:  Ce Shi; Zhengming Xiong; Padmaja Chittepu; Courtney C Aldrich; John R Ohlfest; David M Ferguson
Journal:  ACS Med Chem Lett       Date:  2012-06-14       Impact factor: 4.345

8.  Exquisite selectivity for human toll-like receptor 8 in substituted furo[2,3-c]quinolines.

Authors:  Hari Prasad Kokatla; Diptesh Sil; Subbalakshmi S Malladi; Rajalakshmi Balakrishna; Alec R Hermanson; Lauren M Fox; Xinkun Wang; Anshuman Dixit; Sunil A David
Journal:  J Med Chem       Date:  2013-08-15       Impact factor: 7.446

9.  Structure-Based Design of Human TLR8-Specific Agonists with Augmented Potency and Adjuvanticity.

Authors:  Mallesh Beesu; Giuseppe Caruso; Alex C D Salyer; Karishma K Khetani; Diptesh Sil; Mihiri Weerasinghe; Hiromi Tanji; Umeharu Ohto; Toshiyuki Shimizu; Sunil A David
Journal:  J Med Chem       Date:  2015-09-22       Impact factor: 7.446

10.  Structure Based Modeling of Small Molecules Binding to the TLR7 by Atomistic Level Simulations.

Authors:  Francesco Gentile; Marco A Deriu; Ginevra Licandro; Alessio Prunotto; Andrea Danani; Jack A Tuszynski
Journal:  Molecules       Date:  2015-05-08       Impact factor: 4.411

View more
  8 in total

1.  Plant-derived oleanolic acid ameliorates markers of subclinical inflammation and innate immunity activation in diet-induced pre-diabetic rats.

Authors:  Mlindeli Gamede; Lindokuhle Mabuza; Phikelelani Ngubane; Andile Khathi
Journal:  Ther Adv Endocrinol Metab       Date:  2020-07-27       Impact factor: 3.565

2.  Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.

Authors:  Jordan R Hunt; Peter A Kleindl; K Ryan Moulder; Thomas E Prisinzano; M Laird Forrest
Journal:  Bioorg Med Chem Lett       Date:  2019-11-09       Impact factor: 2.823

Review 3.  Advances in Understanding the Initial Steps of Pruritoceptive Itch: How the Itch Hits the Switch.

Authors:  Shirin Kahremany; Lukas Hofmann; Arie Gruzman; Guy Cohen
Journal:  Int J Mol Sci       Date:  2020-07-10       Impact factor: 5.923

4.  Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC).

Authors:  Vidhi Khanna; Hyunjoon Kim; Wenqiu Zhang; Peter Larson; Manan Shah; Thomas S Griffith; David Ferguson; Jayanth Panyam
Journal:  Sci Rep       Date:  2021-02-08       Impact factor: 4.379

5.  Discovery of new TLR7 agonists by a combination of statistical learning-based QSAR, virtual screening, and molecular dynamics.

Authors:  Ardavan Abiri; Masoud Rezaei; Mohammad Hossein Zeighami; Younes Vaezpour; Leili Dehghan; Maedeh KhorramGhahfarokhi
Journal:  Inform Med Unlocked       Date:  2021-11-15

Review 6.  Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles.

Authors:  Deepender Kaushik; Arshpreet Kaur; Nikolai Petrovsky; Deepak B Salunke
Journal:  RSC Med Chem       Date:  2021-05-14

7.  Tetrasubstituted imidazoles as incognito Toll-like receptor 8 a(nta)gonists.

Authors:  Yi Yang; Adam Csakai; Shuangshuang Jiang; Christina Smith; Hiromi Tanji; Jian Huang; Torey Jones; Kentaro Sakaniwa; Lindsey Broadwell; Chengrui Shi; Subada Soti; Umeharu Ohto; Yaohui Fang; Shu Shen; Fei Deng; Toshiyuki Shimizu; Hang Yin
Journal:  Nat Commun       Date:  2021-07-16       Impact factor: 14.919

Review 8.  Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants.

Authors:  Sachin Bhagchandani; Jeremiah A Johnson; Darrell J Irvine
Journal:  Adv Drug Deliv Rev       Date:  2021-05-29       Impact factor: 15.470

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.